Abstract
Coronavirus disease 2019 (COVID-19), the highly contagious illness caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the globe, becoming one of the most challenging public health crisis of our times. SARS-CoV-2 can cause severe disease associated with multiple organ damage. Cancer patients have a higher risk of SARS-CoV-2 infection and death. While the virus uses angiotensin-converting enzyme 2 (ACE2) as the primary entry receptor, the recent experimental and clinical findings suggest that some tumor markers, including CD147 (basigin), can provide an additional entry for SARS-CoV-2 infection through binding to the viral spike (S) protein. In the absence of specific viral drugs, blocking of CD147 might be a way to prevent virus invasion. Identifying other target proteins is of high importance as targeting the alternative receptors for SARS-CoV-2 might open up a promising avenue for the treatment of COVID-19 patients, including those who have cancer.
Keywords:
Basigin; CD147; COVID-19; Emmprin; SARS-CoV-2; spike protein.
© 2020 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
MeSH terms
-
Angiotensin-Converting Enzyme 2 / genetics
-
Angiotensin-Converting Enzyme 2 / metabolism
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Basigin / antagonists & inhibitors*
-
Basigin / genetics
-
Basigin / immunology
-
Biomarkers, Tumor / antagonists & inhibitors*
-
Biomarkers, Tumor / genetics
-
Biomarkers, Tumor / immunology
-
COVID-19 / genetics
-
COVID-19 / immunology
-
COVID-19 / virology
-
COVID-19 Drug Treatment*
-
Clinical Trials as Topic
-
Host-Pathogen Interactions / drug effects
-
Host-Pathogen Interactions / genetics
-
Host-Pathogen Interactions / immunology
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / immunology
-
Neoplasms / virology
-
Protein Binding
-
Receptors, Virus / genetics
-
Receptors, Virus / metabolism
-
SARS-CoV-2 / drug effects
-
SARS-CoV-2 / immunology
-
SARS-CoV-2 / pathogenicity
-
Severity of Illness Index
-
Spike Glycoprotein, Coronavirus / antagonists & inhibitors*
-
Spike Glycoprotein, Coronavirus / genetics
-
Spike Glycoprotein, Coronavirus / metabolism
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
BSG protein, human
-
Biomarkers, Tumor
-
Receptors, Virus
-
Spike Glycoprotein, Coronavirus
-
metuximab
-
spike protein, SARS-CoV-2
-
meplazumab
-
Basigin
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2